Last reviewed · How we verify
PRGN-2009 plus Pembrolizumab
At a glance
| Generic name | PRGN-2009 plus Pembrolizumab |
|---|---|
| Sponsor | Precigen, Inc |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer (PHASE2)
- Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PRGN-2009 plus Pembrolizumab CI brief — competitive landscape report
- PRGN-2009 plus Pembrolizumab updates RSS · CI watch RSS
- Precigen, Inc portfolio CI